MXB-22,510
Broad-spectrum anti-infective (bacterial, fungal, viral)
PreclinicalActive
Key Facts
Indication
Broad-spectrum anti-infective (bacterial, fungal, viral)
Phase
Preclinical
Status
Active
Company
About Maxwell Biosciences
Maxwell Biosciences is pioneering a 'Biomimetic Immune System' using its Claromer® platform to develop stable, broad-spectrum anti-infective drugs. Its lead candidate, MXB-22,510, has shown preclinical efficacy against a wide range of drug-resistant bacteria, fungi, and viruses, including pan-coronavirus and influenza. Founded in 2016 with roots in U.S. government-funded research, the company is preparing for human trials in 2026 and aims to provide a universal therapeutic solution for biodefense and age-related infectious disease.
View full company profile